| Literature DB >> 2201397 |
R J Shearer1, J H Davies, M Dowsett, P R Malone, A Hedley, D Cunningham, R C Coombes.
Abstract
We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve of 19 patients (63%), who had relapsed following castration and other therapies, gained significant pain relief following weekly intramuscular injections of 4-OHA. Five patients (31%) experienced a transient 'tumour flare', represented by an increase in bone pain soon after commencing treatment. The mechanism of action of 4-OHA in palliating patients with advanced prostatic cancer is obscure at present, but may represent an important new treatment modality which may lead to greater insight into prostatic biology.Entities:
Mesh：
Substances：
Year: 1990 PMID： 2201397 PMCID： PMC1971817 DOI： 10.1038/bjc.1990.276
Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640